Thank of product QX and Good call. quarter. very you happy us consecutive execute. joining further report XXXX our morning, demonstrates We I'm for IRadimed's record on our offerings strength tenth and today's to ability to believe you, operator. thank the
the while release morning's were XX% GAAP a representing quarter per came revenue at in the this quarter over share XXXX increase $X.XX, earnings 'XX. share, announced, million, As increase per for earnings QX quarter were of $XX.X over diluted non-GAAP fourth XXXX. diluted XX.X% fourth a fourth $X.XX press
new gain in we winning Our quarter. MRI entire acceptance team's sizable commitment, And patient continues focus orders pulls with together have some achieved.
The performances to past signs and provide the once can-do to this attitude vital again, monitor customers.
of again And older orders for are brought to our product forward gain start very year, targeted surprised quarters regarding growth Year, monitor were received plan pleasantly pump having our Thusly, this expanded we keep guidance in of of an by coming pumps learn our of With as for the the comfortable a the performance field pushing bullish shall with continue of a strong. and ahead plan MRI we of business selling plan. providing older in direction in in IV the have we New program We in feel moment. market.
Sales after came through to once you new we further replacements XXXX. and to significant share these the QX which business, for
customer had it I the reduce reducing backlog. we in us indicated striving products supply resources lead which deliver provides earlier strong we and bookings allows As in to QX. a backlog thus backlog XXXX, which arise, although what our started means visibility we plan may and and of with as lead issues And excellent times, less reallocate turn maneuver reduce time, the to are to in
long have However, we backlog delivery lead time preferred. and customer we a than bit more still associated
to This shall in are our continues others by testing materials again, in quarters. XX coming FDA IV being but have XX we shave test acceleration the underway, I'd time done XXXX lead the pump. provide another is which massive to continue I are the regarding production new end. spoken through of we reaching and some finished, progress, delivery.
Once progress like while MRI an surrounded that's Previously, with So efforts, the been still to days of
FDA and the I forward. move been, in other Our do have impacting help support now materially XXX(k) minimize one we consultants as costs Still, relationship these but the feel help time. we necessary rising technical involved, assistance. to them success are not external for statutory see deeply and review And ensure for fact, outside and earnings
we or We needs will FDA and half cause such of feel submission help carefully. filing XXX(k) are that help external for additional the input external refiling time back May should new such additional would that would the inputs different clearance in the time planning XXXX's clearance. consider in We plan in for to the But XXXX. us produce concise the our revenue XXXX, more XXX(k). device elements show a shorten from Expecting so we QX suggest lead the
our full $X.XX. million report to for we GAAP guidance year XXXX, share -- sorry, of earnings million, to share XX XX $XX to expect of per to for diluted non-GAAP As per diluted $X.XX the $XX and $X.XX with $X.XX revenues to earnings
$X.XX guidance, For GAAP the million first diluted quarter million to earnings expect $X.XX $XX diluted $XX.X per per revenue to of $X.XX. share earnings and of of to we XXXX and financial non-GAAP share $X.XX of
the contribution to XXXX still a deliver pump strategy such XX% XXXX. performance in close in and I'd highlight to The replacement by FMD helped of is in overall rose to earlier. year. from monitor are XXXX, XX% the to All shareholders increased relatively we IV spoke I sales like XXXX very Now all, and increased of product some to during look the sales patient revenue, forward threefold proud XXXX. small XXXX device to a The device sales our MR of details over our
like and the CFO, Jack? to results the over call the quarter year. to for I'd Jack our Now financial review Glenn, turn to